Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 18/20 | 0.87 |
| ▸ | AKT2 | P31751 | 12/20 | 0.87 |
| ▸ | AKT3 | Q9Y243 | 7/20 | 0.87 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.72 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.69 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388417 | 1.00 | AKT1 (0.87) | AKT1AKT2AKT3TDP1RUVBL1 | |
| SCHEMBL5348455 | 0.93 | AKT1 (1.00) | AKT1AKT2AKT3TDP1RUVBL1 | |
| SCHEMBL14501032 | 0.93 | AKT1 (0.84) | AKT1AKT2AKT3TDP1RUVBL1 | |
| SCHEMBL5313477 | 0.93 | AKT1 (0.84) | AKT1AKT2AKT3TDP1RUVBL1 | |
| SCHEMBL14419056 | 0.90 | AKT1 (1.00) | AKT1AKT2AKT3TDP1RUVBL1 | |
| SCHEMBL14419057 | 0.90 | AKT1 (1.00) | AKT1AKT2AKT3TDP1RUVBL1 | |
| SCHEMBL14501018 | 0.90 | AKT1 (0.83) | AKT1AKT2AKT3TDP1RUVBL1 | |
| SCHEMBL14501020 | 0.90 | AKT1 (0.83) | AKT1AKT2AKT3TDP1RUVBL1 | |
| SCHEMBL1434365 | 0.90 | AKT1 (0.86) | AKT1AKT2AKT3TDP1RUVBL1 | |
| SCHEMBL5401310 | 0.89 | AKT1 (1.00) | AKT1AKT2AKT3TDP1RUVBL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009243-A1 | METHODS OF PREPARING T CELLS FOR T CELL THERAPY | KITE PHARMA INC (US) | 2024-01-11 | — | — | US | claimed |
| US-11723923-B2 | Methods of preparing T cells for T cell therapy | KITE PHARMA, INC. (US) | 2023-08-15 | — | — | US | claimed |
| US-20200206265-A1 | Methods of Preparing T Cells for T Cell Therapy | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-07-02 | — | — | US | claimed |
| US-20170136063-A1 | Methods of Preparing T Cells for T Cell Therapy | KITE PHARMA, INC. (US) | 2017-05-18 | — | — | US | claimed |
| EP-1494676-B1 | FUSED QUINOXALINE DERIVATIVES AS INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2013-05-08 | — | — | EP | claimed |
| US-7273869-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1494676-A4 | FUSED QUINOXALINE DERIVATIVES AS INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2006-05-10 | — | — | EP | claimed |
| US-20050159422-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2005-07-21 | — | — | US | claimed |
| EP-1494676-A1 | FUSED QUINOXALINE DERIVATIVES AS INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2005-01-12 | — | — | EP | claimed |
| WO-2003086404-A1 | FUSED QUINOXALINE DERIVATIVES AS INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | claimed |
| US-12551530-B2 | Immune cell function | KITE PHARMA, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20240009243-A1 | METHODS OF PREPARING T CELLS FOR T CELL THERAPY | KITE PHARMA INC (US) | 2024-01-11 | — | — | US | disclosed |
| WO-2023215825-A1 | METHODS FOR IMPROVING T CELL EFFICACY | Immatics US, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230355678-A1 | METHODS FOR IMPROVING T CELL EFFICACY | Immatics US, Inc. | 2023-11-09 | — | — | US | disclosed |
| US-11723923-B2 | Methods of preparing T cells for T cell therapy | KITE PHARMA, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-7273869-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1494676-A4 | FUSED QUINOXALINE DERIVATIVES AS INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050159422-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2005-07-21 | — | — | US | disclosed |
| EP-1494676-A1 | FUSED QUINOXALINE DERIVATIVES AS INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003086404-A1 | FUSED QUINOXALINE DERIVATIVES AS INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551530-B2 | Immune cell function | IL18, PBK, ICOS | AKT1 1750/4885AKT2 1667/4885AKT3 1973/4885 |
| US-20170136063-A1 | Methods of Preparing T Cells for T Cell Therapy | IL15, CD4, IL2 | AKT1 40/4885AKT2 35/4885AKT3 45/4885 |
| US-20050159422-A1 | Inhibitors of akt activity | AKT1, AKT2, AKT3 | AKT1 1/4885AKT2 2/4885AKT3 3/4885 |
| US-20230355678-A1 | METHODS FOR IMPROVING T CELL EFFICACY | ICOS, IL2, CD4 | AKT1 72/4885AKT2 89/4885AKT3 122/4885 |
| US-20200206265-A1 | Methods of Preparing T Cells for T Cell Therapy | IL15, CD4, IL2 | AKT1 40/4885AKT2 35/4885AKT3 45/4885 |
| US-11723923-B2 | Methods of preparing T cells for T cell therapy | IL15, CD4, IL2 | AKT1 40/4885AKT2 35/4885AKT3 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.